Guinn, Barbara - University of Hull - Department of Biology / Biomedical Sciences

个人简介

BSc (Hons) Genetics (1991) University of Wales, Aberystwyth Doctor of Philosophy (Medicine) (1995) University of Wales College of Medicine, Cardiff 1995-1996 Postdoctoral Fellow, Autologous Bone Marrow Transplant Unit, University of Toronto, Canada 1996-1999 Postdoctoral Fellow, Department of Immunology, University of Toronto, Canada 1999-2008 Senior Research Fellow, Department of Haematological Medicine, King’s College London. 2008-2010 Senior Research Fellow, Cancer Sciences Unit, University of Southampton 2010-2012 Senior Lecturer, Department of Life Sciences, University of Bedfordshire 2012-2016 Reader in Biochemistry and Cell Biology, University of Bedfordshire 2016 – Present Reader in Biomedical Science, University of Hull

研究领域

My lab focuses on the identification of novel targets for the immunotherapy of cancer using SEREX, microarray and proto-arrays. We focus on difficult to treat diseases such as acute lymphocytic leukaemia, prostate and ovarian cancer. A number of epitopes from these antigens have been inserted into DNA vaccines and tested for their suitability for use in clinical trials. We have also used tetramer arrays to prioritise the recognition of epitopes within tumour antigens by patient T cells, and hope to use the technique to monitor how immune responses change with patient treatment. A number of the antigens that we have identified, have restricted expression in cancer, and also act as biomarkers of diagnosis and survival. We have identified novel genes and gained insight into their function in health and disease. With regards to ovarian cancer we have identified a novel cancer-testis antigen, which is expressed in >70% of stage I and II ovarian cancer patient samples but not healthy adjacent or endometrial tissues. We are now examining the presence of protein biomarkers in body fluids from ovarian cancer patients (urine and serum) using ELISA and protein arrays.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Brooks SE, Bonney S, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA. (2015) Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. Public Library of Science One, 10, e0140483. Collin JF, Wells J, Czepulkowski B, Lyne L, Duriez P, Banham AH, Mufti GJ, Guinn BA. (2015) A novel zinc finger gene, ZNF465, is inappropriately expressed in presentation acute myeloid leukaemia cells. Genes, Chromosomes & Cancer, 54, 288-302. Hardwick NR, Buchan S, Ingram W, Khan G, Vittes G, Rice J, Pulford K, Mufti GJ, Stevenson FK, Guinn BA. (2013) An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide. Cancer Immunity, 13, 16-26. Liberante FG, Pellagatti A, Boncheva V, Bowen DT, Mills KI, Boultwood J, Guinn BA. (2013). High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British Journal of Haematology, 162, 282-284. Guinn BA, Greiner J, Schmitt M, Mills KI. (2009) Elevated expression of the leukaemia associated antigen SSX2IP predicts good survival in acute myeloid leukaemia patients who lack detectable cytogenetic rearrangements. Blood, 113, 1203-1204.